TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2971693
Drug: Topical tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tretinoin (0.05%)
Study: 31125055
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg vaccine (month regimen)
Study: 31125055
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg vaccine (month regimen)
Study: 28024163
Drug: Psychoeducation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducation group (PEG) intervention program, delivered weekly in a group format over 3 weeks
Study: 22676906
Drug: Surface neuromuscular
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surface neuromuscular electrical stimulation for 30 minutes, twice a day for 6 weeks in addition to standardized upper limb therapy
Study: 22676906
Drug: Standardized upper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized upper limb therapy alone
Study: 7790695
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (500 mg daily for 1 year)
Study: 7790695
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical appearance tablets for 1 year)
Study: 2193075
Drug: 5-ASA 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-ASA 500 mg suppositories (Asacol) 3 times a day for 1 month
Study: 154749
Drug: Natural oestrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural oestrogen preparation (piperazine oestrone sulphate)
Study: 12074225
Drug: Systematic methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic methods of evidence-based medicine
Study: 7479624
Drug: Social marketing
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social marketing theory (SMT) recruitment materials in Treatment Hall
Study: 7033426
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (200 mg intramuscularly each week)
Study: 23522799
Drug: 1.8 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g/d n‐3 (1.08g eicosapentoaenoic acid + 0.72 g docosahexaenoic acid)
Study: 23522799
Drug: 40 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g/d walnut
Study: 23522799
Drug: 2.0 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g/d conjugated linoleic acid (CLA)
Study: 20360492
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and midazolam (M&M)
Study: 19212858
Drug: Collagen hydrolysate
Normalized name: collagen, hydrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen hydrolysate (CH) 10 g daily for 6 months
Study: 11864500
Drug: Type I
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type I inactivated vaccine against HFRS
Study: 8668427
Drug: Complex physical
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex physical tasks (e.g., ball throws)
Study: 362893
Drug: Trimethoprim-sulfamethoxazole (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (12 mg/kg/day for 10 days)
Study: 362893
Drug: Sulfamethoxazole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfamethoxazole (50 mg/kg/day for 10 days)
Study: 21052022
Drug: Beta-blocker or
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker or diuretic monotherapy
Study: 21052022
Drug: Beta-blocker or
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker or diuretic-based treatment
Study: 21052022
Drug: Diltiazem-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem-based treatment
Study: 19319994
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication or interpersonal therapy (RCT participants, n=105)
Study: 15554569
Drug: Manualized group-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manualized group-based intervention (weekly 90-min sessions over 6 weeks)
Study: 11133640
Drug: Meperidine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (25 mg IV)
Study: 11133640
Drug: Clonidine (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.15 mg IV)
Study: 11133640
Drug: Urapidil (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (25 mg IV)
Study: 7881704
Drug: Captopril (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (12.5 mg t.i.d.)
Study: 3144541
Drug: Fleroxacin 600
Normalized name: fleroxacin
DrugBank: Fleroxacin (DB04576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 600 mg
Study: 28606503
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy (SUPPORT)
Study: 18303486
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg nebicapone
Study: 18303486
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg nebicapone
Study: 16782911
Drug: RT/PCV (radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT/PCV (radiotherapy followed by six cycles of standard procarbazine, lomustine, and vincristine chemotherapy)
Study: 14653888
Drug: Goserelin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (single dose depot preparation)
Study: 2880811
Drug: Suanzaorentang (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suanzaorentang (250 mg t.i.d.)
Study: 2880811
Drug: Diazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (2 mg t.i.d.)
Study: 2880811
Drug: Suanzaorentang (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suanzaorentang (250 mg t.i.d.) and Diazepam (2 mg t.i.d.)
Study: 20805528
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (100 mg/kg per day)
Study: 8866037
Drug: One 7
Normalized name: menaquinone 7
DrugBank: Menaquinone 7 (DB13075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 7 day 17 beta-estradiol transdermal delivery system (TDS)
Study: 8866037
Drug: Two 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 7 day 17 beta-estradiol transdermal delivery systems (TDSs)
Study: 1310913
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg daily for 6 months
Study: 1310913
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg daily for 6 months
Study: 1310913
Drug: Placebo after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo after 6 months of active treatment
Study: 30826761
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg daily) in combination with isoniazid (H), rifampicin (R), ethambutol (E), and pyrazinamide (Z) for the first 2 months, followed by HRE for 4 months.
Study: 30826761
Drug: Standard 6-month
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 6-month anti-TB treatment regimen (HRZE) for the first 2 months, followed by HRE for 4 months.
Study: 28489273
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil 5% applied twice daily
Study: 28489273
Drug: Low-level light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level light therapy (LLLT) using the helmet iGrow® device for 25 minutes 3 days weekly
Study: 28489273
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of topical minoxidil 5% twice daily and LLLT for 25 minutes 3 days weekly for 4 months
Study: 22988653
Drug: clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clindamycin phosphate 1.2%‐‐benzoyl peroxide (BPO) 2.5% gel
Study: 22988653
Drug: adapalene 0.1%‐‐BPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: adapalene 0.1%‐‐BPO 2.5% gel
Study: 18005286
Drug: 7% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7% hydrogen peroxide (HP) bleaching solution
Study: 18005286
Drug: 5% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% hydrogen peroxide (HP) bleaching solution
Study: 10354808
Drug: Alcohol treatment
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol treatment (mean blood alcohol content = 0.07%)
Study: 28523482
Drug: Patient-driven titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-driven titration of BIAsp 30
Study: 25180608
Drug: Investigator-driven titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator-driven titration of BIAsp 30
Study: 22288732
Drug: Liraglutide (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.2 mg after 6 weeks, 1.8 mg after 12 weeks)
Study: 19192221
Drug: Varenicline 1
Normalized name: varenicline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 1 mg bd
Study: 17428108
Drug: Glycoalkaloid (BEC-5)
Normalized name: racepinephrine
DrugBank: Racepinephrine (DB11124)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoalkaloid (BEC-5) cream
Study: 12042428
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (7576 microg or 25,000 IU of retinol palmitate daily)
Study: 10210264
Drug: NXX-066 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: NXX-066 20 mg BID
Study: 10210264
Drug: NXX-066 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: NXX-066 30 mg BID
Study: 10210264
Drug: NXX-066 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: NXX-066 40 mg BID
Study: 10210264
Drug: NXX-066 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: NXX-066 50 mg BID
Study: 10210264
Drug: NXX-066 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: NXX-066 60 mg BID
Study: 10210264
Drug: NXX-066 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: NXX-066 70 mg BID
Study: 10210264
Drug: NXX-066 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: NXX-066 80 mg BID
Study: 21486974
Drug: 4-drug fixed-dose
Normalized name: 4-MIXED TRACE ELEMENTS INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-drug fixed-dose combination (FDC) regimen (rifampicin, isoniazid, pyrazinamide, ethambutol)
Study: 21486974
Drug: Separate drugs
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate drugs regimen
Study: 21486974
Drug: 4-drug fixed-dose
Normalized name: 4-MIXED TRACE ELEMENTS INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-drug fixed-dose combination (FDC) regimen
Study: 7481864
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus doxorubicin plus escalating doses of paclitaxel
Study: 6290980
Drug: pirprofen 200
Normalized name: Carprofen
DrugBank: Carprofen (DB00821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pirprofen 200 mg
Study: 6290980
Drug: pirprofen 400
Normalized name: Carprofen
DrugBank: Carprofen (DB00821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pirprofen 400 mg
Study: 6290980
Drug: ketoprofen 150
Normalized name: ketoprofen 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketoprofen 150 mg
Study: 31832778
Drug: Intravenous triglyceride
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous triglyceride (TG) infusion
Study: 24691771
Drug: Group-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based exercise program (twice a week for 3 months)
Study: 17650794
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of prednisone and cyclophosphamide (CTX) plus Chinese medicine Langchuang Recipe after gamma‐globulin treatment
Study: 12037371
Drug: 6 mmol/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mmol/l sodium hexafluorosilicate‐calcium chloride‐based two‐solution fluoride rinse
Study: 12037371
Drug: 12 mmol/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mmol/l sodium fluoride rinse
Study: 7608262
Drug: Naltrexone (Nal;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (Nal; 100 mg/day) during estradiol (E2) and progesterone (P) administration (Nal 1)
Study: 7608262
Drug: Naltrexone (Nal;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (Nal; 100 mg/day) during pulsatile GnRH administration (Nal 2)
Study: 7608262
Drug: Pulsatile GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsatile GnRH administration (10 micrograms/pulse, iv, every 90 min)
Study: 29426436
Drug: Topical silicone
Normalized name: silicones Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical silicone gel (Dermatix Ultra) applied to one scar for 2 months
Study: 10405234
Drug: Sulpiride (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (50 mg every 8 hours for 24 hours)
Study: 10405234
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg every 8 hours for 24 hours)
Study: 2180390
Drug: Cephalothin 2
Normalized name: cephalothin 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalothin 2 g X 4 on the day of operation
Study: 2180390
Drug: Methicillin 1
Normalized name: methicillin 1 g injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methicillin 1 g X 4 on the day of operation
Study: 27329448
Drug: Darapladib (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darapladib (selective Lp-PLA2 inhibitor)
Study: 20053788
Drug: Ariva/Stonewall (smokeless
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ariva/Stonewall (smokeless tobacco lozenges)
Study: 15817428
Drug: Hydrocortisone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (100 mg loading dose followed by 0.18 mg/kg/h continuous infusion for 6 days)
Study: 10906641
Drug: Sunscreen alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunscreen alone (gel)
Study: 10906641
Drug: Sunscreen alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunscreen alone (cream)
Study: 8814740
Drug: Helium ion
Normalized name: Helium
DrugBank: Helium (DB09155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Helium ion therapy
Study: 8814740
Drug: 125I radioactive
Normalized name: fibrinogen (125I)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125I radioactive plaque therapy
Study: 8814740
Drug: Helium ion
Normalized name: Helium
DrugBank: Helium (DB09155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Helium ion therapy and 125I brachytherapy
Study: 31627889
Drug: Colloid group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid group (HES solution 750 ml)
Study: 31627889
Drug: Crystalloid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid group (LR solution 2825 ml)
Study: 29430176
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of alpha 1 antitrypsin (AAT)
Study: 26444030
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continuing for 24 h after surgery.
Study: 20964833
Drug: Sulphasalazine and
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulphasalazine and hydroxychloroquine (treatment A)
Study: 20964833
Drug: Infliximab (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (treatment B)
Study: 17347185
Drug: Phenylephrine 100
Normalized name: phenylephrine 100 mcg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine 100 microg ml‐1
Study: 17347185
Drug: Ephedrine 4.5
Normalized name: chlorpheniramine-pseudoephedrine 4.5 mg-75 mg/5 mL oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 4.5 mg ml‐1
Study: 12077742
Drug: High-isoflavone soy
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-isoflavone soy diet (73 mg/d isoflavone)
Study: 12077742
Drug: Low-isoflavone soy
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-isoflavone soy diet (10 mg/d isoflavone)
Study: 2911850
Drug: Short-term doxorubicin
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term doxorubicin infusion (10 mg/m2/day for 5 days)
Study: 2911850
Drug: Long-term doxorubicin
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term doxorubicin infusion (3 mg/m2/day for 5-104 days)
Study: 2911850
Drug: Short-term doxorubicin
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term doxorubicin infusion
Study: 2911850
Drug: Long-term doxorubicin
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term doxorubicin infusion
Study: 2911850
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of doxorubicin
Study: 31424962
Drug: Herbal extracts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal extracts (mangosteen, Lithospermum officinale, Tribulus terrestris L., Houttuynia cordata Thunb)
Study: 27489211
Drug: TV‐1106 (7.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TV‐1106 (7.5, 15, 50, and 100 mg)
Study: 27489211
Drug: TV‐1106 (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TV‐1106 (7.5 and 15 mg)
Study: 27489211
Drug: TV‐1106 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: TV‐1106 (50 and 100 mg)
Study: 14679674
Drug: Low-dose perindopril/indapamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose perindopril/indapamide (2 mg and 0.625 mg daily)
Study: 14679674
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment of atenolol (50 mg) then losartan (50 mg) then amlodipine (5 mg)
Study: 14679674
Drug: Step-by-step strategy
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step-by-step strategy of valsartan (40 mg then 80 mg then 80 mg plus hydrochlorothiazide 12.5 mg)
Study: 10989766
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplementation (150 mg ferrous sulfate tablets, 50 mg Fe daily)
Study: 10989766
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly iron supplementation (150 mg ferrous sulfate tablets, 50 mg Fe twice weekly)
Study: 10989766
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly iron supplementation (150 mg ferrous sulfate tablets, 50 mg Fe once weekly)
Study: 10989766
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no iron supplement)
Study: 1534832
Drug: Long-term sodium
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term sodium restriction (daily sodium intake reduced to less than 70 mmol)
Study: 31782367
Drug: Fresh pomegranate
Normalized name: Pomegranate
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh pomegranate juice (1.5 mL kg‐1)
Study: 19479153
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of 0.25% bupivacaine
Study: 17229221
Drug: Enteral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutritional therapy (EN group)
Study: 17229221
Drug: Non-nutritional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-nutritional therapy (non-EN group)
Study: 15535487
Drug: Pyridostigmine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine 0.25 mg/kg with glycopyrrolate 0.01 mg/kg at 5 minutes after rocuronium administration
Study: 15535487
Drug: Pyridostigmine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine 0.25 mg/kg with glycopyrrolate 0.01 mg/kg at 1% twitch height (T1) recovery
Study: 15535487
Drug: Pyridostigmine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine 0.25 mg/kg with glycopyrrolate 0.01 mg/kg at 25% twitch height (T25) recovery
Study: 11555061
Drug: Preintervention treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preintervention treatment with parenteral antibiotics (PA) when PA were recommended by the guidelines (n = 127)
Study: 11555061
Drug: Preintervention treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preintervention treatment with oral antibiotics (OA) when OA were indicated by the guidelines (n = 99)
Study: 11555061
Drug: Postintervention treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postintervention treatment with PA and OA according to the guidelines
Study: 10021958
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml saline
Study: 29234746
Drug: 5 or
Normalized name: Acys-5 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 or 6 mm long implants
Study: 12010156
Drug: 10 mm
Normalized name: potassium 10 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mm long implants
Study: 26323921
Drug: Nimotuzumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab (200 mg) with docetaxel (60 mg/m2) and carboplatin (AUC = 5)
Study: 26323921
Drug: Chemotherapy (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (docetaxel 60 mg/m2 and carboplatin AUC = 5)
Study: 26323921
Drug: Nimotuzumab with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab with chemotherapy
Study: 23447123
Drug: Insulin administered
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin administered according to the customary insulin:carbohydrate ratio
Study: 21672597
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from 9-10 mg ISO tar yield cigarette to 4 mg ISO tar yield cigarette
Study: 21672597
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from 4-6 mg ISO tar yield cigarette to 1 mg ISO tar yield cigarette